Sign in Subscribe
COVID-19

COVID-19 Convalescent Plasma Treatment Shows High Survival Rates in B-Cell Depleted Patients

Strategic Insights

— 1 min read

Systematic reviews and individual patient data meta-analysis have shown that COVID-19 convalescent plasma (CCP) treatment is effective in increasing 60-day survival rates in B-cell depleted patients. The study, conducted on a cohort of 570 patients, found that 86.5% of patients survived for 60 days, with 70.1% achieving SARS-CoV-2 clearance and 64.3% showing clinical improvement within 5 days of CCP transfusion. Notably, the study identified a significant association between 60-day survival and the use of vaccine-boosted CCP, which is thought to contain higher levels of neutralizing antibodies.

Key Takeaways:

  • The study included 570 patients from 85 studies, with an overall 60-day survival rate of 86.5%.
  • 70.1% of patients who received CCP treatment achieved SARS-CoV-2 clearance, and 64.3% showed clinical improvement within 5 days.
  • The study found a significant association between 60-day survival and the use of vaccine-boosted CCP (OR=9.49; 95% CI 2.01 to 44.82; p=0.005).
  • There was no significant association between 60-day survival and concomitant remdesivir treatment (OR=1.31; 95% CI 0.66 to 2.61; p=0.440).
  • The study's findings suggest that vaccine-boosted CCP may be particularly beneficial for B-cell depleted patients.

Statistics:

  • 570 patients were included in the study, with an overall 60-day survival rate of 86.5%.
  • 70.1% of patients achieved SARS-CoV-2 clearance, and 64.3% had clinical improvement within 5 days of CCP transfusion.
  • The median age of patients in the study was not specified.
  • The study included data from 85 studies, with a majority being case series and case reports.

Sources:

  • medrxiv.org (Abstract preprint, dated 2025.05.15.25327576v1)
  • PROSPERO (Protocol registration, dated March 1st, 2024, CRD42024516513)
  • World Health Organization (Disease severity classification)

Read more